Introduction
Breast cancer is the second leading cause of cancer-related deaths for women in the United States and one of the leading causes of cancer-related deaths in the world (Jemal et al., 2009) . Tamoxifen, an adjuvant hormone therapy, is commonly prescribed to women with estrogen receptor alpha (ERa)-positive breast cancer. The active metabolite of tamoxifen, 4-hydroxytamoxifen (4-OHT), is a selective estrogen receptor modulator (SERM) that functions as an ERa antagonist in breast tissue and breast cancer cells. As an ERa antagonist, 4-OHT inhibits the expression of genes that induce cell cycle progression thus reducing breast cancer cell proliferation rates (Osborne et al., 1983) . Experiments in vitro show that breast cancer cells treated with tamoxifen for 72 h have decreased IGF-1-dependent IGF-1 receptor (IGF-1R) phosphorylation (Guvakova and Surmacz, 1997) . One potential hypothesis for this observation is 4-OHT-induced accumulation of an extracellular factor that inhibits IGF-1 stimulation in this cell type.
The insulin-like growth factor-1 (IGF-1)-stimulated signal transduction pathway induces breast cancer cell proliferation and survival via activation of the IGF-1R (Arteaga, 1992; Arteaga et al., 1989; Burgaud et al., 1995; Sachdev and Yee, 2001; Yee et al., 1989) . Inhibitors of IGF-1R decrease breast cancer cell proliferation rates, therefore strategies that target this signal transduction pathway have been suggested as a potential therapeutic approach (Li et al., 2009) . IGFBPs are secreted proteins that have been shown to modulate both IGF-dependent and IGF-independent cell signaling (Baxter, 2013; Galiano et al., 1996; Oh et al., 1993) . IGFBPs can modulate IGFdependent signaling by sequestering IGF from IGF-receptors and reducing receptor activation (Butt et al., 1999; Cullen et al., 1990; Figueroa et al., 1993; Yee et al., 1994) . IGF-independent modulation can occur via interaction with other cell surface receptors or can require intracellular mechanisms Galiano et al., 1996; . In MCF-7 breast cancer cells, exogenously expressed IGFBP-1 inhibits IGF-1-induced cell proliferation (Figueroa et al., 1993; Yee et al., 1994) , however it is not clear if breast cancer cells express and secrete IGFBP-1. A role for cAMP and the cAMP-response element-binding protein (CREB) in IGFBP-1 expression has been demonstrated in hepatocytes (Frost et al., 2000; Sugawara et al., 2000) . cAMP activates protein kinase A (PKA) to phosphorylate the CREB transcription factor at serine 133 (Mayr and Montminy, 2001 ). This phosphorylation is required for association with the coactivators CBP and p300 and leads to the activation of promoters containing cAMPresponse elements (CRE) (Chrivia et al., 1993; Kwok et al., 1994; Mayr and Montminy, 2001 ). The IGFBP-1 has been previously analyzed and, among other response elements, this promoter contains a CRE (Frost et al., 2000; Sugawara et al., 2000) .
GPER1 is activated in cells treated with 17b-estradiol (E2) and mediates rapid cell signaling events (Prossnitz and Maggiolini, 2009; Prossnitz et al., 2008; Revankar et al., 2005; Tang et al., 2014) . This receptor is also activated by the GPER1-selective agonist G-1, the pure antiestrogen fulvestrant 780) , and 4-OHT (Maggiolini et al., 2004; Revankar et al., 2005; Thomas and Dong, 2006; Thomas et al., 2005; Vivacqua et al., 2006) . GPER1 activation in breast cancer cells can induce apoptosis and inhibit proliferation via p53-dependent cell cycle arrest (Ariazi et al., 2010; Wei et al., 2014) . Conversely, GPER1 activation has been shown to induce cell proliferation in an epidermal growth factor receptor (EGFR)-dependent manner (Maggiolini et al., 2004; Pandey et al., 2009; Pupo et al., 2012) . More recently, GPER1 has been shown to play a potential role in the development of tamoxifen resistance in vitro (Ignatov et al., 2010; Mo et al., 2013) .
In this contribution, evidence supporting a role for 4-OHTdependent extracellular IGFBP-1 accumulation in the modulation of IGF-1R signaling in breast cancer cells is presented. Furthermore, data herein show that CREB and GPER1 mediate the observed IGFBP-1 induction after 4-OHT treatment and this effect is independent of ERa. IGFBP-1 knockdown by siRNA demonstrated that IGFBP-1 is, at least in part, required for the inhibition of IGF-1-dependent cell signaling associated with 4-OHT treatment. Furthermore, antibody neutralization experiments support a role for extracellular IGFBP-1 in the observed inhibition. Taken together, these data suggest that GPER1-mediated CREB activation results in the accumulation of extracellular IGFBP-1 in 4-OHT-treated breast cancer cells thus revealing a previously unidentified mechanism of tamoxifen action.
Materials and methods

Cell culture and treatment
MCF-7 and SKBr-3 breast cancer cells (ATCC, Manassas, VA) were maintained in DMEM (Life Technologies, Carlsbad, CA) and DMEM/F12 (Life Technologies, Carlsbad, CA), respectively. Maintenance media were supplemented with 10% fetal bovine serum (Life Technologies, Carlsbad, CA). 48 h prior to treatment, cells were washed with 1Â PBS, and phenol red-free DMEM supplemented with 10% charcoal-stripped FBS (Life Technologies, Carlsbad, CA) was added to the cells. After 24 h, cells were washed with 1Â PBS, then serum-starved in phenol red-free DMEM overnight followed by treatment with the indicated dose of G-1, G36 (provided by Jeffrey B. Arterburn, New Mexico State University) or 4-hydroxytamoxifen (4-OHT) (Fluka, St. Louis, MO). G-1, G36 and 4-OHT were dissolved in ethanol (vehicle) and the final concentration of ethanol in medium was 0.1%. For GPER1 inhibition in the cell viability assay, cells were pre-incubated with 1 mM G36 for 30 min prior to 4-OHT treatment.
siRNA transfection
The knockdown experiment was performed as described previously (Ariazi et al., 2010) . Briefly, all cell transfections were performed using Lipofectamine 2000 reagent for 4e6 h in serum-free Opti-MEM (Life Technology, Carlsbad, CA). For siRNA knockdown, cells were transfected with GPER1 siRNA (Ambion, s6053, sense: GGCUGUACAUUGAGCAGAAtt; antisense: UUCUGCUCAAUGUACAGCCtc); ERa siRNA (Ambion, s4823, sense: ACAUCAUCUCGGUUCCGCAtt; antisense: UGCGGAACCGAGAUGAUGUag); CREB1 siRNA (Ambion, 109994, sense: GGUGGAAAAAUGGACUGGCUtt; antisense: AGCCAGUCCAUUUUCCACCtt); IGFBP-1 siRNA (Santa Cruz, sc-39584) or non-targeting siRNA (Ambion, 4390843, negative control #1). After overnight recovery in maintenance media, the transfection was repeated again followed by growing transfected cells in media containing 10% charcoal-striped FBS and analyzed for protein expression (immunoblot) after 48 h.
Total RNA isolation and quantitative PCR analysis
Total RNA was isolated with the PureLink RNA Mini Kit (Life Technologies, Carlsbad CA) with DNase-I following the manufacturer's protocol. cDNA was synthesized from total RNA (1 mg) using the High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA). Quantitative real-time PCR reactions were performed using SYBR Green Master Mix and the 7300 Real-Time PCR system (Bio-Rad, Hercules, CA). RPL30 gene expression was used in all quantitative real-time PCR reaction as an internal reference gene to normalize relative changes in transcript levels. Primers for amplification of human IGFBP-1: forward 5-CTA-TGA-TGG-CTC-GAA-GGC-TC-3, reverse 5-TTC-TTG-TTG-CAG-TTT-GGC-AG-3 (XIE, 2014) and RPL30: forward 5-ACA-GCA-TGC-GGA-AAA-TAC-TAC-3, reverse: 5-AAA-GGA-AAA-TTT-TGC-AGG- TTT-3 (de Jonge et al., 2007) .
Immunoblot analysis
Whole cell extracts were prepared in RIPA buffer containing protease and phosphatase inhibitor cocktails (87785, 78420, Thermo Scientific, Rockford, IL). Cell extract protein concentrations were determined using BCA assay (Thermo Scientific, Rockford, IL).
30e50 mg of whole cell lysates were resolved using Bolt 4e12% BisTris Plus gels (Life Technologies, Carlsbad, CA) and transferred to PVDF membrane. Blots were blocked in Tris-buffered saline-0.1% Tween 20 (1Â TBST) containing 5% fat-free milk at room temperature for 1 h then incubated with primary antibody at room temperature for 2 h using the following antibodies: IGFBP-1 (sc-13097, Santa Cruz Biotechnology, Dallas, TX); GPER1 (sc-48825-R, Santa Cruz Biotechnology, Dallas, TX); phospho-IGF-I receptor beta ( Cruz Biotechnology, Dallas, TX). After washing three times with 1Â TBST, blots were incubated with anti-IgG horseradish peroxidaseconjugated secondary antibody (sc-81178, Santa Cruz Biotechnology, Dallas, TX). Prior to the addition of chemiluminescence reagent (34076, Thermo Scientific, Rockford, IL), blots were washed three times with 1Â TBST. Each blot was stripped using restore plus western blot stripping buffer (46430, Thermo Scientific, Rockford, IL) when necessary to determine equivalent sample loading. Chemiluminescence was detected using Gel Doc™ XR ChemiDoc™ imaging system (BioRad, Hercules, CA) and quantitated using Quantity One ® software (BioRad, Hercules, CA).
Extracellular IGFBP-1 measurement and conditioned medium
Extracellular concentration of IGFBP-1 was determined using human IGFBP-1 ELISA (ab100539, Abcam, Cambridge, MA) following manufacturer's protocol. For immunoblot analysis, protein content of conditioned cell culture medium from treated cells was column concentrated (Pratt and Pollak, 1993 ) about 10-fold using Centrifugal Filter Devices (Ultracel 3K, Milipore, Germany) (Deng et al., 2010) . Also, protease inhibitor cocktail (P1860, Sigma, St. Louis, MA) 10 ml/mL was applied to the cell culture medium during vehicle and drug treatments prior to conditioned medium analysis (Han and Townes-Anderson, 2012; Ween et al., 2011) . After centrifugation, protein concentration was determined using BCA protein assay (Thermo Scientific, Rockford, IL) and 20 mg of concentrated protein was used for immunoblot analysis as previously described. Experiments using conditioned media involved moving culture medium from 4-OHT-treated cultures to cultures previously treated with vehicle and vice versa. After the media was switched, cells were stimulated for 15 min with 50 ng/mL IGF-1.
IGFBP-1 neutralization assay
IGFBP-1 neutralization was performed using anti-IGFBP-1 antibody (Sigma, I2032, monoclonal mouse IgG1). After treating MCF-7 cells for 24 h with 4-OHT to allow for the accumulation of IGFBP-1 in the cell culture medium, the control IgG or IGFBP-1 neutralizing antibody (10 ng/mL) was added for 2 h prior to IGF-1 stimulation.
Cell viability assay
Cells were plated in 96-well plates at a density of 2500 cells per well in DMEM supplemented with 10% fetal bovine serum. 12 h prior to treatment, media were replaced with DMEM supplemented with 1% charcoal-stripped serum (Fagan et al., 2012) , and cell number was determined after five days using Alamar blue reagent (Life Technology, Carlsbad, CA) according to the manufacture's procedure.
Statistical analysis
All statistical analysis was performed by one-way ANOVA, Tukey's test using Kaleidagraph (Synergy Software, Reading, PA). Differences were considered significant if p 0.05 and the error bars are ± SEM.
Results
Conditioned medium from 4-OHT-treated MCF-7 cells inhibited IGF-1-stimulated AKT phosphorylation
Previous reports show that 4-OHT exposure for 72 h inhibits IGF-1R phosphorylation in IGF-1-stimulated breast cancer cells (Guvakova and Surmacz, 1997) , however, the mechanism of inhibition was not identified. Such inhibition is not observed with a 10 min or 8 h treatment with 4-OHT (Lee et al., 1997) suggesting that the observed inhibition may require extracellular accumulation of an inhibitory factor that modulates IGF-1. To determine if inhibition of IGF-1 stimulation in breast cancer cells is dependent on accumulation of an extracellular factor, conditioned medium experiments were performed. AKT phosphorylation was used as an indicator of IGF-1 stimulation in breast cancer cells. After MCF-7 cells were treated for 24 h with 1 mM 4-OHT, conditioned medium was collected and used to replace the medium of naïve, vehicletreated cells. After the medium switch, cells were stimulated with 50 ng/mL IGF-1 for 15 min and the phosphorylation status of AKT (S473) was measured by immunoblot. After stimulation with 50 ng/ mL IGF-1 in conditioned medium obtained from MCF-7 cells treated with 4-OHT, phosphorylation of AKT (S473) was decreased compared to stimulation in conditioned medium from vehicletreated MCF-7 cells (Fig. 1 , lane 4 compared to lane 3). To ensure that the observed inhibition of AKT phosphorylation did not result from the remaining 4-OHT in the conditioned medium, a 15 min 4-OHT treatment was included as a control. Data from this experiment indicated that treatment with 4-OHT for 15 min did not affect IGF-1-stimulated AKT phosphorylation (Supplemental Fig. 1 ). This result is consistent with previously published data showing that a relatively short-term 4-OHT treatment is unable to inhibit IGF-1 signaling (Lee et al., 1997) and indicated that treatment with 4-OHT increased an extracellular factor that modulates IGF-1-stimulation in MCF-7 breast cancer cells.
4-OHT induced IGFBP-1 transcription and extracellular accumulation in MCF-7 cells
Exogenously expressed IGFBP-1 has been previously demonstrated to regulate MCF-7 breast cancer cells (Yee et al., 1994) . To determine if 4-OHT induced endogenous IGFBP-1 transcription, MCF-7 cells were treated with 4-OHT for 24 h and relative IGFBP-1 transcript levels were determined by quantitative real-time PCR (qPCR) analysis. The results indicated a significant and dosedependent increase in IGFBP-1 transcription after treatment with 4-OHT compared to vehicle treatment ( Fig. 2A) . Furthermore, 4-OHT treatment induced the intracellular IGFBP-1 protein levels compared to vehicle treatment (supplemental Fig. 2 ). Since the observed inhibition of IGF-1 stimulation was conferred using conditioned medium from 4-OHT-treated MCF-7 cells, we determined the extracellular accumulation of IGFBP-1. Since the concentration of IGFBPs are quite low in media from MCF-7 cells (Hermani et al., 2013; Pratt and Pollak, 1993; Yee et al., 1994) , the conditioned culture medium from vehicle or 4-OHT-treated MCF-7 cells was column concentrated prior to immunoblot analysis (Deng et al., 2010) to obtain a detectable level of protein in the sample. Using this approach, a dose-dependent increase in extracellular IGFBP-1 was observed after 24 h of treatment with 4-OHT (Fig. 2B ). These data indicated that 4-OHT induced IGFBP-1 transcription and increased extracellular IGFBP-1 protein levels in MCF-7 breast cancer cells.
4-OHT increased phospho-CREB levels to modulate IGFBP-1 transcription in MCF-7 cells
Phosphorylation on CREB transcription factor at serine 133 promotes expression of its target genes via modulation of promoters containing the cAMP-response element (CRE) (Brindle and Montminy, 1992) . The CRE has been identified in the human IGFBP-1 promoter and the regulatory role of CREB in IGFBP-1 expression has been determined (Frost et al., 2000; Sugawara et al., 2000) . CREB phosphorylation at serine 133 is downstream of the cAMP-PKA axis (Gonzalez and Montminy, 1989) . To determine if 4-OHT induced CREB phosphorylation, MCF-7 cells were treated with 4-OHT for 2 h and phospho-CREB levels were determined by immunoblot. Results demonstrated that 4-OHT (100 nM and 1 mM) increased CREB phosphorylation compared with vehicletreated MCF-7 cells (Fig. 3A) . To determine if CREB mediated the observed IGFBP-1 transcription in 4-OHT-treated breast cancer cells, siRNA knockdown of CREB was performed. After CREB knockdown by siRNA, IGFBP-1 transcription was significantly reduced compared to non-targeting control after 4-OHT-treatment (Fig. 3B,C) . Knockdown of CREB expression by~75% compared to non-targeting control CREB expression levels resulted in a~50% reduction in IGFBP-1 mRNA expression. These data indicated that CREB contributes to IGFBP-1 induction and suggests a role for additional modulators in this system. These data demonstrated the involvement of CREB in the observed IGFBP-1 transcription in 4-OHT-treated breast cancer cells.
GPER1-mediated CREB phosphorylation in breast cancer cells
CREB activation by phosphorylation at serine 133 (S133) is downstream of cAMP-activated protein kinase (PKA) (Brindle and Montminy, 1992). While 4-OHT is a well-characterized antagonist for ERa in MCF-7 cells, it has also been shown to function as a GPER1 agonist. Since GPER1 activates adenylyl cyclase (Filardo et al., 2002) and its downstream kinase, PKA, it may play a role in IGFBP-1 expression in 4-OHT-treated breast cancer cells. Furthermore, the involvement of GPER1 in regulation of gene expression through CREB has been previously demonstrated (Karki et al., 2013) . To determine the role of ERa and GPER1 in the observed 4-OHT-induced CREB phosphorylation, siRNA knockdown experiments were performed (Fig. 4A,B) . Phosphorylation of CREB was decreased in GPER1 knockdown cells compared with ERa knockdown and non-targeting control (Fig. 4C) . Together, these experiments demonstrated that decreased ERa expression does not alter the accumulation of phospho-CREB after treatment with 4-OHT and that GPER1 contributes to 4-OHT-induced CREB phosphorylation. To further demonstrate a role for GPER1 activation in the observed CREB phosphorylation, treatment with the GPER1-agonist G-1 was performed and increased CREB phosphorylation in MCF-7 cells was observed (supplemental Fig. 3A) . Furthermore, 4-OHT induced CREB phosphorylation in ERa-negative and GPER1-positive SKBr-3 breast cancer cells (supplemental Fig. 3B ). These data support a role for GPER1 in the observed 4-OHT-induced CREB phosphorylation and that ERa is not a key determinant of CREB phosphorylation after 4-OHT treatment in breast cancer cells.
4-OHT-induced IGFBP-1 expression was GPER1-mediated and inhibits IGF-1 stimulation in MCF-7 cells
To further support our findings that GPER1 mediated the increased IGFBP-1 expression after treatment with 4-OHT, MCF-7 cells were treated with the GPER1-specific agonist G-1. A significant increase in IGFBP-1 transcription was observed after treatment with 100 nM G-1 when compared to vehicle treatment in MCF-7 cells (Supplemental Fig. S4A ). GPER1 knockdown was performed prior to treatment with 4-OHT to demonstrate the involvement of GPER1 in the observed IGFBP-1 induction. When GPER1 protein was reduced in MCF-7 cells, 4-OHT-dependent IGFBP-1 induction was decreased compared with control, nontargeting siRNA (Fig. 5A) . Additionally, 4-OHT significantly increased IGFBP-1 transcription in ERa-negative, GPER1-positive SKBr-3 cells, and GPER1 knockdown significantly reduced IGFBP-1 transcription in SKBr-3 cells after treatment with 4-OHT (Supplemental Fig. S4B, C) . Since GPER1 knockdown reduced IGFBP-1 transcription in 4-OHT-treated cells, the impact on the ability of 4-OHT to inhibit IGF-1 signaling was determined by measuring the changes in phosphorylation of IGF-I receptor b (Y1135/1136), AKT (S473), and ERK1/2 after IGF-1 stimulation. In GPER1 knockdown cells, the inhibition of IGF-1 stimulation after 4-OHT treatment was significantly less than control cells (Fig. 5B) . To determine if GPER1 contributes to decreased MCF-7 cell viability after 4-OHT treatment, cells were treated with 4-OHT in the presence or absence of the GPER1 antagonist G36 (Dennis et al., 2011) and cell viability was determined after five-days of treatment. Consistent with results from others (Fagan et al., 2012; Mo et al., 2013) , these data showed that 4-OHT significantly decreased MCF-7 cell viability, and this effect is inhibited by GPER1 antagonism (Fig. 5C ). These data demonstrated that in 4-OHT-treated breast cancer cells, GPER1 contributes to the inhibition of IGF-1 signaling and decreases cell viability.
PKA inhibitor decreased IGFBP-1 induction in 4-OHT-treated MCF-7 cells
Our data showed that GPER1 contributes to 4-OHT-induced CREB phosphorylation and IGFBP-1 transcription. GPER1 activation can also result in EGFR activation by release of heparin-bounded EGF (Filardo et al., 2000) , and it has been shown that EGFR signaling pathway can induce CREB phosphorylation at S133 (Vanhoutte et al., 1999; Xing et al., 1998) . To determine if the observed IGFBP-1 induction is cAMP-dependent or EGFR-mediated, MCF-7 cells were pretreated with either the PKA inhibitor H-89 or the EGFR inhibitor AG1478 prior to 4-OHT treatment. Immunoblot analysis demonstrated that pretreatment with H-89, but not AG1478, inhibited 4-OHT-induced CREB phosphorylation (Fig. 6A) . Furthermore, the effect of each inhibitor on 4-OHT-induced IGFBP-1 transcription was determined. Consistent with reduced CREB phosphorylation after pretreatment with PKA inhibitor, 4-OHTinduced IGFBP-1 transcription was also reduced (Fig. 6B) . These results indicated that GPER1-mediated IGFBP-1 transcription dependent on the phosphorylation of CREB by PKA.
Inhibition of IGF-1-stimulated cell signaling after 4-OHT treatment required IGFBP-1
Data thus far demonstrate that conditioned medium collected from MCF-7 cells treated with 4-OHT for 24 h inhibited IGF-1 stimulation. In addition, IGFBP-1 transcription and extracellular accumulation were observed after treatment with 4-OHT for 24 h. To determine if extracellular IGFBP-1 inhibited IGF-1 stimulation in MCF-7 cells, both antibody-mediated neutralization and knockdown of IGFBP-1 were performed. Antibody-mediated neutralization of IGFBP-1 (10 ng/mL,~66.6 pM) rescued IGF-1 stimulation in 4-OHT-treated MCF-7 cells (Fig. 7A, lane 3 compared to lane 4) . A magnitude higher dose of neutralizing antibody (100 ng/mL) had a similar effect on IGF-1 stimulation while a magnitude lower concentration (1 ng/mL) was slightly less effective compare to 10 ng/ mL (data not shown). Addition of control antibody (10 ng/mL for The results are representative of three independent experiments, and the error bars are SEM.
2 h) did not alter the previously observed phosphorylation of IGF-1R-mediated signal transduction components after IGF-1 stimulation (Fig. 7A, lane 4) . However, the neutralizing antibody did not result in a complete reversal of inhibition suggesting that other extracellular factors in the conditioned medium from 4-OHTtreated cells may modulate IGF-1 signaling. IGFBP-1 knockdown significantly reduced IGFBP-1 expression in MCF-7 cells (Fig. 7B ) and reduced the ability of 4-OHT treatment to inhibit IGF-1-dependent cell signaling (Fig. 7C) . These results support a role for IGFBP-1 in the inhibition of IGF-1 stimulation in 4-OHT-treated breast cancer cells. One potential mechanism of the observed inhibition is sequestration of IGF-1 via binding to IGFBP-1. It has been reported that an equimolar or near equimolar concentration for the IGF and IGFBP is required for inhibition by sequestration (Butt et al., 1999; Cullen et al., 1990; Figueroa et al., 1993; Kijimura et al., 2005; Yee et al., 1994) . To determine if the observed induction of IGFBP-1 results in a sufficient increase in IGFBP-1 molarity to achieve inhibition IGF-1 signaling by sequestration, the concentration of IGFBP-1 in conditioned medium was determined by ELISA. The concentration of IGFBP-1 in conditioned medium from MCF-7 cells was significantly increased from 29.4 (þ/À 1.9) pg/mL to 81.8 (þ/À 4.6) pg/mL for vehicle and 1 mM 4-OHTtreated cells, respectively. 81.8 pg/mL of IGFBP-1 is approximately 2.7 pM and the IGF-1 concentration in our studies is approximately 7 nM. These results do not support sequestration of IGF-1 by IGFBP-1 as the mechanism of action in this system as such a mechanism would require a higher molarity for IGFBP-1. However, siRNA knockdown of IGFBP-1 and antibody neutralization experiments demonstrate that IGFBP-1 is a critical component of the observed inhibition of IGF-1-dependent cell signaling after 4-OHT treatment in breast cancer cells. 
Discussion
In an effort to identify potential extracellular components of tamoxifen action in breast cancer cells, the expression and accumulation of IGFBP-1 in 4-OHT-treated breast cancer cell cultures was identified. Data herein show that GPER1 and CREB mediate the observed IGFBP-1 induction after 4-OHT treatment and this effect is independent of ERa. Although the concentration of extracellular IGFBP-1 is not likely sufficient for the inhibition of IGF-1-dependent cell signaling by IGF-1 sequestration, IGFBP-1 knockdown demonstrated that IGFBP-1 is, at least in part, required for the inhibition of IGF-1-dependent cell signaling after 4-OHT treatment. Furthermore, antibody-mediated neutralization experiments support a role for extracellular IGFBP-1 in the observed inhibition. Taken together, these data suggest that GPER1-mediates the accumulation of extracellular IGFBP-1 in 4-OHT-treated breast cancer cells and that this accumulation of IGFBP-1 results in the inhibition of IGF-1-dependent cell signaling.
E2-dependent proliferation of ERa-positive breast cancer cells by activation of ERa has been well studied and ERa antagonism is a critical component of tamoxifen action in this cell type (Frasor et al., 2004; Johnston et al., 1992; Ring and Dowsett, 2004; Sharma et al., 2006) . In addition to E2-dependent proliferation mediated by ERa, breast cancer cell proliferation is also induced by IGF-1R activation (Lee et al., 1997) . Several mechanisms of crosstalk between ERa and IGF-1R have been identified. For example, E2 induces IGF-1R expression and activation in ERa-positive breast cancer cells (Huynh et al., 1996; Lee et al., 1997; Song et al., 2007) . Also, IGF-1 stimulates ligand-independent ERa-mediated transcription that may lead to cell proliferation (Becker et al., 2011; Castano et al., 1997) . Less understood is the modulation of ERa/IGF-1R crosstalk after tamoxifen treatment in ERa-positive breast cancer cells. However, there is evidence that 4-OHT inhibits E2-stimulated IGF-1R expression (Lee et al., 1999) . Data herein provide evidence for a novel mechanism of action by which 4-OHT treatment increases extracellular IGFBP-1 to inhibit IGF-1 stimulation in breast cancer cells. These findings contribute to the understanding of the complex crosstalk mechanisms between E2 and IGF-1 signaling in breast cancer cells.
Activated CREB induces IGFBP-1 transcription via cAMPresponse element (CRE) in the IGFBP-1 promoter (Frost et al., 2000; Sugawara et al., 2000) . More recently, it has been shown that 4-OHT treatment activates CREB downstream of GPER1 in rat astrocytes (Karki et al., 2013) . Based on these published results, it was hypothesized that CREB activation downstream of GPER1 induced IGFBP-1 expression in 4-OHT-treated MCF-7 cells. In this submission, CREB knockdown experiments demonstrated the involvement of CREB in the observed IGFBP-1 expression after 4-OHT treatment. This result suggested that CREB activation in this context inhibits breast cancer cell proliferation by inhibiting growth factor signaling. Although CREB binds directly to the IGFBP-1 promoter in other cell types (Suwanichkul et al., 1993) , CREB binding to the IGFBP-1 promoter was not determined in breast cancer cells. Future experimentation will need to be performed to determine the molecular mechanisms IGFBP-1 transcription in the presence of 4-OHT with emphasis on CREB and other transcription factors such as FoxO1 that has been shown to modulate IGFBP-1 in other cell types (Durham et al., 1999; Kim et al., 2003) .
GPER1 activation in MCF-7 cells induces p21 expression in a p53-dependent manner (Ariazi et al., 2010; Wei et al., 2014) and it has been shown that p-CREB potentiates p53 transcriptional activity (Giebler et al., 2000) . Taken together, these results suggest that CREB activation downstream of GPER1 may play an inhibitory role in ERa-positive breast cancer cells. In contrast, CREB activation induces proliferation in tamoxifen-resistant breast cancer cells and other cancer cell types (Catalano et al., 2014; Daniel et al., 2014; Nguyen et al., 2014; Sofi et al., 2003) . Furthermore, increased CREB expression in breast tumors is associated with poor prognosis, shorter survival and higher risk of metastasis (Chhabra et al., 2007; Fan et al., 2012) . Additional experimentation will be required to gain a thorough understanding with regard to the role of CREB during tamoxifen treatment.
This study is the first to our knowledge to characterize the mechanism of endogenous IGFBP1 production in breast cancer cells and the first to identify extracellular factors that mediate tamoxifen action. Interestingly, elevated IGFBP-1 levels are observed in sera obtained from breast cancer patients treated with tamoxifen (Bonanni et al., 2001; Helle et al., 1996; Johansson et al., 2008; Lahti et al., 1994; Lonning et al., 1992) , but the mechanism for the observed increase in IGFBP-1 has not been studied. Besides IGFBP-1, other IGFBPs may be induced by tamoxifen treatment in our experiments and function to modulate IGF-1-dependent cell signaling. The induction of IGFBP-3 protein in 4-OHT-treated MCF-7 cells has been shown previously (Pratt and Pollak, 1993) , however, IGFBP-4 expression reduced by 4-OHT in MCF-7 cells (Pratt and Pollak, 1993; Qin et al., 1999) . Further studies aimed at understanding the role of IGFBPs (and other secreted proteins) during tamoxifen treatment will need to be completed to gain a thorough understanding of extracellular mechanisms of tamoxifen action.
IGFBPs can modulate cells via both intracellular and extracellular mechanisms and previous studies on IGFBP function have demonstrated various mechanisms of action other than classical, IGF-1 sequestration (Figueroa et al., 1993; Lee et al., 1997; Murphy, 1998) . While the data presented here do not support sequestration of IGF-1 by IGFBP-1 as a mechanism for the observed modulation of IGF-1-depdendent signaling, IGFBP-1 knockdown and antibody neutralization experiments demonstrate that IGFBP-1 is part of the mechanism of inhibition. The observed inhibition of IGF-1-dependent cell signaling in these studies could also be modulated by other IGFBPs or secreted factors that have not yet been identified. The discovery of an alternate mechanism if IGFBP-1-mediated inhibition and the identification of additional secreted factors involved in the observed inhibition will require further investigation.
Sustained GPER1 activation results in the development of tamoxifen resistance using in vitro models (Ignatov et al., 2010; Mo et al., 2013) suggesting a role for GPER1 in tamoxifen action and the development of tamoxifen resistance. Interestingly, tamoxifenresistant breast cancer cells have decreased IGF-1R expression and an increased dependence on other growth factors such as EGF (Fagan et al., 2012; Fan et al., 2007) . In the context of the present data, it is hypothesized that increased extracellular IGFBP-1 downstream of GPER1 activation during tamoxifen treatment inhibits IGF-1-dependent cell signaling and provides selective pressure in favor of breast cancer cells that are not dependent on IGF-1R signaling for survival and proliferation. Additional studies are required to determine if increased extracellular IGFBP-1 accumulation may be involved in the development of tamoxifen resistance.
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